We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutrali... Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. Show more
TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. Zura Bio...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.58 | -22.5680933852 | 2.57 | 2.64 | 1.99 | 276159 | 2.29551669 | CS |
4 | -0.29 | -12.7192982456 | 2.28 | 2.715 | 1.99 | 644134 | 2.4188548 | CS |
12 | -2.92 | -59.4704684318 | 4.91 | 4.98 | 1.99 | 469543 | 3.01339107 | CS |
26 | -1.69 | -45.9239130435 | 3.68 | 5.07 | 1.99 | 458131 | 3.54329993 | CS |
52 | -1.86 | -48.3116883117 | 3.85 | 6.35 | 1.99 | 360099 | 3.52762274 | CS |
156 | -6.01 | -75.125 | 8 | 37.55 | 1.99 | 358839 | 6.07612011 | CS |
260 | -6.01 | -75.125 | 8 | 37.55 | 1.99 | 358839 | 6.07612011 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions